One Charles Private Wealth Services LLC Takes Position in Merck & Co., Inc. (NYSE:MRK)

One Charles Private Wealth Services LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 3,384 shares of the company’s stock, valued at approximately $263,000.

Other hedge funds have also recently bought and sold shares of the company. Resources Investment Advisors LLC. grew its stake in shares of Merck & Co., Inc. by 9.1% during the 2nd quarter. Resources Investment Advisors LLC. now owns 35,473 shares of the company’s stock worth $2,759,000 after acquiring an additional 2,971 shares during the period. Sigma Planning Corp grew its stake in shares of Merck & Co., Inc. by 15.3% during the 1st quarter. Sigma Planning Corp now owns 73,515 shares of the company’s stock worth $5,667,000 after acquiring an additional 9,762 shares during the period. Davidson Capital Management Inc. grew its stake in shares of Merck & Co., Inc. by 13.9% during the 2nd quarter. Davidson Capital Management Inc. now owns 15,982 shares of the company’s stock worth $1,243,000 after acquiring an additional 1,956 shares during the period. Brandywine Oak Private Wealth LLC grew its stake in shares of Merck & Co., Inc. by 57.7% during the 2nd quarter. Brandywine Oak Private Wealth LLC now owns 29,581 shares of the company’s stock worth $2,300,000 after acquiring an additional 10,829 shares during the period. Finally, Naples Global Advisors LLC grew its stake in shares of Merck & Co., Inc. by 4.6% during the 1st quarter. Naples Global Advisors LLC now owns 81,214 shares of the company’s stock worth $6,261,000 after acquiring an additional 3,578 shares during the period. Institutional investors own 71.83% of the company’s stock.

Several research analysts have commented on the company. JPMorgan Chase & Co. cut their target price on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, June 9th. Zacks Investment Research upgraded Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 target price for the company in a research note on Tuesday, August 24th. Truist assumed coverage on Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $92.00 target price for the company. Morgan Stanley downgraded Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $90.00 to $85.00 in a research note on Tuesday, September 7th. Finally, Truist Securities assumed coverage on Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $76.79 target price for the company. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $91.09.

Shares of MRK traded up $0.58 during trading hours on Wednesday, reaching $72.69. 92,639 shares of the company’s stock traded hands, compared to its average volume of 11,229,302. The stock has a market cap of $184.01 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. The company has a current ratio of 1.31, a quick ratio of 1.06 and a debt-to-equity ratio of 0.72. The firm’s 50 day simple moving average is $76.68 and its 200-day simple moving average is $76.59. Merck & Co., Inc. has a 12 month low of $71.71 and a 12 month high of $86.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.31. The firm had revenue of $11.40 billion during the quarter, compared to the consensus estimate of $11.21 billion. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. During the same quarter last year, the company posted $1.37 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.51 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 7th. Stockholders of record on Wednesday, September 15th will be given a dividend of $0.65 per share. The ex-dividend date is Tuesday, September 14th. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.58%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 43.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Story: What sectors are represented in the Hang Seng index?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.